Cargando…

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy

Objective: Immune checkpoint inhibitors (ICIs) have recently demonstrated promising performance in improving the prognosis of urological cancer patients. The goal of this meta-analysis was to determine the impact of PPI use on the clinical outcomes of urological cancer patients receiving ICI therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lilong, Chen, Chen, Chai, Dongqi, Li, Chunlei, Kuang, Tianrui, Liu, Li, Dong, Keshuai, Deng, Wenhong, Wang, Weixing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549125/ https://www.ncbi.nlm.nih.gov/pubmed/36225582 http://dx.doi.org/10.3389/fphar.2022.1018411

Ejemplares similares

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Mycobiota and C-Type Lectin Receptors in Cancers: Know thy Neighbors
por: Zhang, Lilong, et al.
Publicado: (2022)

Alterations of gut mycobiota profiles in intrahepatic cholangiocarcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma
por: Zhang, Lilong, et al.
Publicado: (2023)

Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
por: Zhang, Lilong, et al.
Publicado: (2023)

Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma
por: Kuang, Tianrui, et al.
Publicado: (2023)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy
por: Zhang, Lilong, et al.
Publicado: (2023)

Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2023)

Receptor-interacting protein in malignant digestive neoplasms
por: Zhang, Lilong, et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

The Prognostic Significance and Potential Mechanism of Prolyl 3-Hydroxylase 1 in Hepatocellular Carcinoma
por: Li, Chunlei, et al.
Publicado: (2022)

The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis
por: Zhang, Lilong, et al.
Publicado: (2020)

Construction of a Nomogram to Predict Overall Survival in Patients with Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Kuang, Tianrui, et al.
Publicado: (2023)

Effects of hormones on intestinal stem cells
por: Liu, Li, et al.
Publicado: (2023)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

Exploratory Study of Tegaserod for Dyspepsia in Women Receiving PPIs for Heartburn
por: Vakil, Nimish, et al.
Publicado: (2008)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Key Molecules of Fatty Acid Metabolism in Gastric Cancer
por: Li, Chunlei, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Rebamipide with Proton Pump Inhibitors (PPIs) versus PPIs Alone for the Treatment of Endoscopic Submucosal Dissection-Induced Ulcers: A Meta-analysis
por: Liu, Junyuan, et al.
Publicado: (2020)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
por: Tsai, Tsung-Han, et al.
Publicado: (2023)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vo0ac8k1ivr88689abnr40i2s4